Global Companion Diagnostics for Oncology Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 246418
  • calendar_today Published On: Dec, 2021
  • file_copy Pages: 156
  • list Medical Devices
Buy @ $3500

The Companion Diagnostics for Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Companion Diagnostics for Oncology size is estimated to be USD million in 2026 from USD million in 2020, with a change % between 2020 and 2021. The global Companion Diagnostics for Oncology market size is expected to grow at a CAGR of % for the next five years.

Market segmentation

Companion Diagnostics for Oncology market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Market segment by Application, can be divided into

Pharmaceutical and Biopharmaceutical Companies

Contract Research Organizations

Laboratories

Others

Market segment by players, this report covers

Agilent Technologies

Illumina

Roche

BioMérieux

Foundation Medicine

ArcherDX

Qiagen

Thermo Fisher Scientific

Amoy Diagnostics

Abbott

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Companion Diagnostics for Oncology product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Companion Diagnostics for Oncology, with revenue, gross margin and global market share of Companion Diagnostics for Oncology from 2019 to 2021.

Chapter 3, the Companion Diagnostics for Oncology competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Companion Diagnostics for Oncology market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Companion Diagnostics for Oncology research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Companion Diagnostics for Oncology

1.2 Classification of Companion Diagnostics for Oncology by Type

1.2.1 Overview: Global Companion Diagnostics for Oncology Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Companion Diagnostics for Oncology Revenue Market Share by Type in 2020

1.2.3 Polymerase Chain Reaction (PCR)

1.2.4 Next-Generation Sequencing (NGS)

1.3 Global Companion Diagnostics for Oncology Market by Application

1.3.1 Overview: Global Companion Diagnostics for Oncology Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Pharmaceutical and Biopharmaceutical Companies

1.3.3 Contract Research Organizations

1.3.4 Laboratories

1.3.5 Others

1.4 Global Companion Diagnostics for Oncology Market Size & Forecast

1.5 Global Companion Diagnostics for Oncology Market Size and Forecast by Region

1.5.1 Global Companion Diagnostics for Oncology Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Companion Diagnostics for Oncology Market Size by Region, (2016-2021)

1.5.3 North America Companion Diagnostics for Oncology Market Size and Prospect (2016-2026)

1.5.4 Europe Companion Diagnostics for Oncology Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Companion Diagnostics for Oncology Market Size and Prospect (2016-2026)

1.5.6 South America Companion Diagnostics for Oncology Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Companion Diagnostics for Oncology Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Companion Diagnostics for Oncology Market Drivers

1.6.2 Companion Diagnostics for Oncology Market Restraints

1.6.3 Companion Diagnostics for Oncology Trends Analysis

2 Company Profiles

2.1 Agilent Technologies

2.1.1 Agilent Technologies Details

2.1.2 Agilent Technologies Major Business

2.1.3 Agilent Technologies Companion Diagnostics for Oncology Product and Solutions

2.1.4 Agilent Technologies Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Agilent Technologies Recent Developments and Future Plans

2.2 Illumina

2.2.1 Illumina Details

2.2.2 Illumina Major Business

2.2.3 Illumina Companion Diagnostics for Oncology Product and Solutions

2.2.4 Illumina Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Illumina Recent Developments and Future Plans

2.3 Roche

2.3.1 Roche Details

2.3.2 Roche Major Business

2.3.3 Roche Companion Diagnostics for Oncology Product and Solutions

2.3.4 Roche Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Roche Recent Developments and Future Plans

2.4 BioMérieux

2.4.1 BioMérieux Details

2.4.2 BioMérieux Major Business

2.4.3 BioMérieux Companion Diagnostics for Oncology Product and Solutions

2.4.4 BioMérieux Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 BioMérieux Recent Developments and Future Plans

2.5 Foundation Medicine

2.5.1 Foundation Medicine Details

2.5.2 Foundation Medicine Major Business

2.5.3 Foundation Medicine Companion Diagnostics for Oncology Product and Solutions

2.5.4 Foundation Medicine Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Foundation Medicine Recent Developments and Future Plans

2.6 ArcherDX

2.6.1 ArcherDX Details

2.6.2 ArcherDX Major Business

2.6.3 ArcherDX Companion Diagnostics for Oncology Product and Solutions

2.6.4 ArcherDX Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 ArcherDX Recent Developments and Future Plans

2.7 Qiagen

2.7.1 Qiagen Details

2.7.2 Qiagen Major Business

2.7.3 Qiagen Companion Diagnostics for Oncology Product and Solutions

2.7.4 Qiagen Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Qiagen Recent Developments and Future Plans

2.8 Thermo Fisher Scientific

2.8.1 Thermo Fisher Scientific Details

2.8.2 Thermo Fisher Scientific Major Business

2.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Product and Solutions

2.8.4 Thermo Fisher Scientific Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Thermo Fisher Scientific Recent Developments and Future Plans

2.9 Amoy Diagnostics

2.9.1 Amoy Diagnostics Details

2.9.2 Amoy Diagnostics Major Business

2.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Product and Solutions

2.9.4 Amoy Diagnostics Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Amoy Diagnostics Recent Developments and Future Plans

2.10 Abbott

2.10.1 Abbott Details

2.10.2 Abbott Major Business

2.10.3 Abbott Companion Diagnostics for Oncology Product and Solutions

2.10.4 Abbott Companion Diagnostics for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Abbott Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Companion Diagnostics for Oncology Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Companion Diagnostics for Oncology Players Market Share

3.2.2 Top 10 Companion Diagnostics for Oncology Players Market Share

3.2.3 Market Competition Trend

3.3 Companion Diagnostics for Oncology Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Companion Diagnostics for Oncology Revenue and Market Share by Type (2016-2021)

4.2 Global Companion Diagnostics for Oncology Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Companion Diagnostics for Oncology Revenue Market Share by Application (2016-2021)

5.2 Companion Diagnostics for Oncology Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Companion Diagnostics for Oncology Revenue by Type (2016-2026)

6.2 North America Companion Diagnostics for Oncology Revenue by Application (2016-2026)

6.3 North America Companion Diagnostics for Oncology Market Size by Country

6.3.1 North America Companion Diagnostics for Oncology Revenue by Country (2016-2026)

6.3.2 United States Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

6.3.3 Canada Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

6.3.4 Mexico Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Companion Diagnostics for Oncology Revenue by Type (2016-2026)

7.2 Europe Companion Diagnostics for Oncology Revenue by Application (2016-2026)

7.3 Europe Companion Diagnostics for Oncology Market Size by Country

7.3.1 Europe Companion Diagnostics for Oncology Revenue by Country (2016-2026)

7.3.2 Germany Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

7.3.3 France Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

7.3.5 Russia Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

7.3.6 Italy Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Companion Diagnostics for Oncology Revenue by Type (2016-2026)

8.2 Asia-Pacific Companion Diagnostics for Oncology Revenue by Application (2016-2026)

8.3 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region

8.3.1 Asia-Pacific Companion Diagnostics for Oncology Revenue by Region (2016-2026)

8.3.2 China Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

8.3.3 Japan Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

8.3.4 South Korea Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

8.3.5 India Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

8.3.7 Australia Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Companion Diagnostics for Oncology Revenue by Type (2016-2026)

9.2 South America Companion Diagnostics for Oncology Revenue by Application (2016-2026)

9.3 South America Companion Diagnostics for Oncology Market Size by Country

9.3.1 South America Companion Diagnostics for Oncology Revenue by Country (2016-2026)

9.3.2 Brazil Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

9.3.3 Argentina Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Companion Diagnostics for Oncology Revenue by Type (2016-2026)

10.2 Middle East & Africa Companion Diagnostics for Oncology Revenue by Application (2016-2026)

10.3 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country

10.3.1 Middle East & Africa Companion Diagnostics for Oncology Revenue by Country (2016-2026)

10.3.2 Turkey Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

10.3.4 UAE Companion Diagnostics for Oncology Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Companion Diagnostics for Oncology Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Companion Diagnostics for Oncology Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Companion Diagnostics for Oncology Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Companion Diagnostics for Oncology Revenue (USD Million) by Region (2016-2021)

Table 5. Global Companion Diagnostics for Oncology Revenue Market Share by Region (2021-2026)

Table 6. Agilent Technologies Corporate Information, Head Office, and Major Competitors

Table 7. Agilent Technologies Major Business

Table 8. Agilent Technologies Companion Diagnostics for Oncology Product and Solutions

Table 9. Agilent Technologies Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Illumina Corporate Information, Head Office, and Major Competitors

Table 11. Illumina Major Business

Table 12. Illumina Companion Diagnostics for Oncology Product and Solutions

Table 13. Illumina Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Roche Corporate Information, Head Office, and Major Competitors

Table 15. Roche Major Business

Table 16. Roche Companion Diagnostics for Oncology Product and Solutions

Table 17. Roche Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. BioMérieux Corporate Information, Head Office, and Major Competitors

Table 19. BioMérieux Major Business

Table 20. BioMérieux Companion Diagnostics for Oncology Product and Solutions

Table 21. BioMérieux Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Foundation Medicine Corporate Information, Head Office, and Major Competitors

Table 23. Foundation Medicine Major Business

Table 24. Foundation Medicine Companion Diagnostics for Oncology Product and Solutions

Table 25. Foundation Medicine Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. ArcherDX Corporate Information, Head Office, and Major Competitors

Table 27. ArcherDX Major Business

Table 28. ArcherDX Companion Diagnostics for Oncology Product and Solutions

Table 29. ArcherDX Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Qiagen Corporate Information, Head Office, and Major Competitors

Table 31. Qiagen Major Business

Table 32. Qiagen Companion Diagnostics for Oncology Product and Solutions

Table 33. Qiagen Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Thermo Fisher Scientific Corporate Information, Head Office, and Major Competitors

Table 35. Thermo Fisher Scientific Major Business

Table 36. Thermo Fisher Scientific Companion Diagnostics for Oncology Product and Solutions

Table 37. Thermo Fisher Scientific Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Amoy Diagnostics Corporate Information, Head Office, and Major Competitors

Table 39. Amoy Diagnostics Major Business

Table 40. Amoy Diagnostics Companion Diagnostics for Oncology Product and Solutions

Table 41. Amoy Diagnostics Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Abbott Corporate Information, Head Office, and Major Competitors

Table 43. Abbott Major Business

Table 44. Abbott Companion Diagnostics for Oncology Product and Solutions

Table 45. Abbott Companion Diagnostics for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Global Companion Diagnostics for Oncology Revenue (USD Million) by Players (2019-2021)

Table 47. Global Companion Diagnostics for Oncology Revenue Share by Players (2019-2021)

Table 48. Breakdown of Companion Diagnostics for Oncology by Company Type (Tier 1, Tier 2 and Tier 3)

Table 49. Companion Diagnostics for Oncology Players Head Office, Products and Services Provided

Table 50. Companion Diagnostics for Oncology Mergers & Acquisitions in the Past Five Years

Table 51. Companion Diagnostics for Oncology New Entrants and Expansion Plans

Table 52. Global Companion Diagnostics for Oncology Revenue (USD Million) by Type (2016-2021)

Table 53. Global Companion Diagnostics for Oncology Revenue Share by Type (2016-2021)

Table 54. Global Companion Diagnostics for Oncology Revenue Forecast by Type (2021-2026)

Table 55. Global Companion Diagnostics for Oncology Revenue by Application (2016-2021)

Table 56. Global Companion Diagnostics for Oncology Revenue Forecast by Application (2021-2026)

Table 57. North America Companion Diagnostics for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 58. North America Companion Diagnostics for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 59. North America Companion Diagnostics for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 60. North America Companion Diagnostics for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 61. North America Companion Diagnostics for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 62. North America Companion Diagnostics for Oncology Revenue by Country (2021-2026) & (USD Million)

Table 63. Europe Companion Diagnostics for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 64. Europe Companion Diagnostics for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 65. Europe Companion Diagnostics for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 66. Europe Companion Diagnostics for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 67. Europe Companion Diagnostics for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 68. Europe Companion Diagnostics for Oncology Revenue by Country (2021-2026) & (USD Million)

Table 69. Asia-Pacific Companion Diagnostics for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 70. Asia-Pacific Companion Diagnostics for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 71. Asia-Pacific Companion Diagnostics for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 72. Asia-Pacific Companion Diagnostics for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 73. Asia-Pacific Companion Diagnostics for Oncology Revenue by Region (2016-2021) & (USD Million)

Table 74. Asia-Pacific Companion Diagnostics for Oncology Revenue by Region (2021-2026) & (USD Million)

Table 75. South America Companion Diagnostics for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 76. South America Companion Diagnostics for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 77. South America Companion Diagnostics for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 78. South America Companion Diagnostics for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 79. South America Companion Diagnostics for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 80. South America Companion Diagnostics for Oncology Revenue by Country (2021-2026) & (USD Million)

Table 81. Middle East & Africa Companion Diagnostics for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 82. Middle East & Africa Companion Diagnostics for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 83. Middle East & Africa Companion Diagnostics for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 84. Middle East & Africa Companion Diagnostics for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 85. Middle East & Africa Companion Diagnostics for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 86. Middle East & Africa Companion Diagnostics for Oncology Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Companion Diagnostics for Oncology Picture

Figure 2. Global Companion Diagnostics for Oncology Revenue Market Share by Type in 2020

Figure 3. Polymerase Chain Reaction (PCR)

Figure 4. Next-Generation Sequencing (NGS)

Figure 5. Companion Diagnostics for Oncology Revenue Market Share by Application in 2020

Figure 6. Pharmaceutical and Biopharmaceutical Companies Picture

Figure 7. Contract Research Organizations Picture

Figure 8. Laboratories Picture

Figure 9. Others Picture

Figure 10. Global Companion Diagnostics for Oncology Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 11. Global Companion Diagnostics for Oncology Revenue and Forecast (2016-2026) & (USD Million)

Figure 12. Global Companion Diagnostics for Oncology Revenue Market Share by Region (2016-2026)

Figure 13. Global Companion Diagnostics for Oncology Revenue Market Share by Region in 2020

Figure 14. North America Companion Diagnostics for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. Europe Companion Diagnostics for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Asia-Pacific Companion Diagnostics for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. South America Companion Diagnostics for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Middle East and Africa Companion Diagnostics for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Companion Diagnostics for Oncology Market Drivers

Figure 20. Companion Diagnostics for Oncology Market Restraints

Figure 21. Companion Diagnostics for Oncology Market Trends

Figure 22. Agilent Technologies Recent Developments and Future Plans

Figure 23. Illumina Recent Developments and Future Plans

Figure 24. Roche Recent Developments and Future Plans

Figure 25. BioMérieux Recent Developments and Future Plans

Figure 26. Foundation Medicine Recent Developments and Future Plans

Figure 27. ArcherDX Recent Developments and Future Plans

Figure 28. Qiagen Recent Developments and Future Plans

Figure 29. Thermo Fisher Scientific Recent Developments and Future Plans

Figure 30. Amoy Diagnostics Recent Developments and Future Plans

Figure 31. Abbott Recent Developments and Future Plans

Figure 32. Global Companion Diagnostics for Oncology Revenue Share by Players in 2020

Figure 33. Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 34. Global Top 3 Players Companion Diagnostics for Oncology Revenue Market Share in 2020

Figure 35. Global Top 10 Players Companion Diagnostics for Oncology Revenue Market Share in 2020

Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 37. Global Companion Diagnostics for Oncology Revenue Share by Type in 2020

Figure 38. Global Companion Diagnostics for Oncology Market Share Forecast by Type (2021-2026)

Figure 39. Global Companion Diagnostics for Oncology Revenue Share by Application in 2020

Figure 40. Global Companion Diagnostics for Oncology Market Share Forecast by Application (2021-2026)

Figure 41. North America Companion Diagnostics for Oncology Sales Market Share by Type (2016-2026)

Figure 42. North America Companion Diagnostics for Oncology Sales Market Share by Application (2016-2026)

Figure 43. North America Companion Diagnostics for Oncology Revenue Market Share by Country (2016-2026)

Figure 44. United States Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 45. Canada Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 46. Mexico Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Europe Companion Diagnostics for Oncology Sales Market Share by Type (2016-2026)

Figure 48. Europe Companion Diagnostics for Oncology Sales Market Share by Application (2016-2026)

Figure 49. Europe Companion Diagnostics for Oncology Revenue Market Share by Country (2016-2026)

Figure 50. Germany Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 51. France Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. United Kingdom Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Russia Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. Italy Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Asia-Pacific Companion Diagnostics for Oncology Sales Market Share by Type (2016-2026)

Figure 56. Asia-Pacific Companion Diagnostics for Oncology Sales Market Share by Application (2016-2026)

Figure 57. Asia-Pacific Companion Diagnostics for Oncology Revenue Market Share by Region (2016-2026)

Figure 58. China Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. Japan Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. South Korea Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. India Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Southeast Asia Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Australia Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. South America Companion Diagnostics for Oncology Sales Market Share by Type (2016-2026)

Figure 65. South America Companion Diagnostics for Oncology Sales Market Share by Application (2016-2026)

Figure 66. South America Companion Diagnostics for Oncology Revenue Market Share by Country (2016-2026)

Figure 67. Brazil Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. Argentina Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Middle East and Africa Companion Diagnostics for Oncology Sales Market Share by Type (2016-2026)

Figure 70. Middle East and Africa Companion Diagnostics for Oncology Sales Market Share by Application (2016-2026)

Figure 71. Middle East and Africa Companion Diagnostics for Oncology Revenue Market Share by Country (2016-2026)

Figure 72. Turkey Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Saudi Arabia Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. UAE Companion Diagnostics for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Methodology

Figure 76. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz